(VIANEWS) – Corcept Therapeutics Incorporated (CORT), BioMarin Pharmaceutical (BMRN), Agree Realty Corporation (ADC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Corcept Therapeutics Incorporated (CORT)
35.4% sales growth and 21.91% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $1.05.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 28.73. Meaning, the purchaser of the share is investing $28.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.91%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 8% and a negative 14.3%, respectively.
2. BioMarin Pharmaceutical (BMRN)
13.7% sales growth and 4.22% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $1.06.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 70.82. Meaning, the purchaser of the share is investing $70.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.22%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 17.2% and 133.3%, respectively.
Yearly Top and Bottom Value
BioMarin Pharmaceutical’s stock is valued at $75.07 at 16:22 EST, way under its 52-week high of $99.56 and above its 52-week low of $73.68.
Previous days news about BioMarin Pharmaceutical(BMRN)
- According to Zacks on Tuesday, 11 June, "Texas Pacific Land (TPL), BioMarin Pharmaceutical (BMRN), Warner Music (WMG), Nextracker (NXT), Altair Engineering (ALTR) and RB Global (RBA) will replace Werner Enterprises (WERN), Integra Lifesciences (IART), Penn Entertainment (PENN), Grocery Outlet (GO), Leggett & Platt (LEG) and Hertz Global (HTZ), respectively in the S&P MidCap 400. "
3. Agree Realty Corporation (ADC)
12.8% sales growth and 3.48% return on equity
Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of June 30, 2020, the Company owned and operated a portfolio of 936 properties, located in 46 states and containing approximately 18.4 million square feet of gross leasable area. The common stock of Agree Realty Corporation is listed on the New York Stock Exchange under the symbol "ADC".
Earnings Per Share
As for profitability, Agree Realty Corporation has a trailing twelve months EPS of $1.69.
PE Ratio
Agree Realty Corporation has a trailing twelve months price to earnings ratio of 36.09. Meaning, the purchaser of the share is investing $36.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.48%.
4. T. Rowe Price Group (TROW)
5.8% sales growth and 19.17% return on equity
T. Rowe Price Group, Inc. is a publicly owned investment manager. The firm provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. It launches and manages equity and fixed income mutual funds. The firm invests in the public equity and fixed income markets across the globe. It employs fundamental and quantitative analysis with a bottom-up approach. The firm utilizes in-house and external research to make its investments. It employs socially responsible investing with a focus on environmental, social, and governance issues. It makes investment in late-stage venture capital transactions and usually invests between $3 million and $5 million. The firm was previously known as T. Rowe Group, Inc. and T. Rowe Price Associates, Inc. T. Rowe Price Group, Inc. was founded in 1937 and is based in Baltimore, Maryland, with additional offices in Colorado Springs, Colorado; Owings Mills, Maryland; San Francisco, California; New York, New York; Philadelphia, Pennsylvania; Tampa, Florida; Toronto, Ontario; Hellerup, Denmark; Amsterdam, The Netherlands; Luxembourg, Grand Duchy of Luxembourg; Zurich, Switzerland; Dubai, United Arab Emirates; London, United Kingdom; Sydney, New South Wales; Hong Kong; Tokyo, Japan; Singapore; Frankfurt, Shanghai, China; Germany, Madrid, Spain, Milan, Italy, Stockholm, Sweden, Melbourne, Australia, Amsterdam, Netherlands and Washington, DC.
Earnings Per Share
As for profitability, T. Rowe Price Group has a trailing twelve months EPS of $7.76.
PE Ratio
T. Rowe Price Group has a trailing twelve months price to earnings ratio of 14.84. Meaning, the purchaser of the share is investing $14.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.17%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.8%, now sitting on 6.67B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 9.4% and 3.2%, respectively.
5. Regeneron Pharmaceuticals (REGN)
5.7% sales growth and 15.28% return on equity
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $34.78.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 26.01. Meaning, the purchaser of the share is investing $26.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.28%.
